The Role of (1R,2R)-2-(3,4-Difluorophenyl)cyclopropanecarboxylic Acid in Novel Drug Synthesis
In the relentless pursuit of novel therapeutic agents, the chemical industry relies on a diverse array of specialized building blocks. Among these, chiral intermediates like (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid (CAS: 220352-36-3) are indispensable. Its unique structural features, including the difluorophenyl group and the cyclopropane ring with defined stereochemistry, make it a prized intermediate for synthetic organic chemists and pharmaceutical researchers. Understanding its role and sourcing it reliably is key to advancing drug discovery.
Unlocking Therapeutic Potential with a Key Intermediate
The primary significance of (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid lies in its application as a precursor in the synthesis of advanced pharmaceuticals. The incorporation of fluorine atoms often enhances a drug candidate's metabolic stability, lipophilicity, and binding affinity, leading to improved efficacy and bioavailability. The chiral cyclopropane ring adds a specific three-dimensional orientation crucial for interacting with biological targets. As a result, this intermediate is vital for the development of compounds targeting various disease areas, including cardiovascular conditions.
Why Purchase (1R,2R)-2-(3,4-Difluorophenyl)cyclopropanecarboxylic Acid?
For pharmaceutical R&D departments and contract manufacturing organizations (CMOs), the decision to purchase this specific intermediate is driven by several factors:
- Stereospecific Synthesis: The defined (1R,2R) configuration is critical for producing enantiomerically pure final products, ensuring targeted pharmacological activity and minimizing off-target effects.
- Structural Versatility: The carboxylic acid functional group allows for a wide range of derivatization reactions, enabling chemists to build complex molecular architectures efficiently.
- Supplier Reliability: Sourcing from a reliable manufacturer is paramount. Companies seek suppliers who can guarantee consistent purity (often >95%), timely delivery, and competitive pricing for bulk quantities. Purchasing from established suppliers ensures your project timelines are met.
- Cost-Efficiency in Development: While specialized, acquiring this intermediate from efficient manufacturers, particularly those based in China, can significantly reduce the cost of early-stage research and later-stage clinical trial material production.
Navigating the Supply Chain
When looking to buy (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid, it's crucial to engage with suppliers who provide comprehensive product documentation, including Certificates of Analysis (CoA) and Material Safety Data Sheets (MSDS). Verifying the CAS number (220352-36-3) and supplier credentials is a standard practice. Many global pharmaceutical companies choose to source such intermediates from manufacturers in China due to the sector's advanced capabilities in fine chemical synthesis and cost-effective production. Identifying a trusted manufacturer and supplier ensures not just the quality of the material but also the security of your supply chain.
In summary, (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid is more than just a chemical compound; it's a gateway to developing life-saving medications. By understanding its significance and strategically sourcing it from reputable manufacturers, researchers and developers can accelerate their path to innovative pharmaceutical solutions.
Perspectives & Insights
Bio Analyst 88
“Navigating the Supply ChainWhen looking to buy (1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid, it's crucial to engage with suppliers who provide comprehensive product documentation, including Certificates of Analysis (CoA) and Material Safety Data Sheets (MSDS).”
Nano Seeker Pro
“Verifying the CAS number (220352-36-3) and supplier credentials is a standard practice.”
Data Reader 7
“Many global pharmaceutical companies choose to source such intermediates from manufacturers in China due to the sector's advanced capabilities in fine chemical synthesis and cost-effective production.”